TheraRadar
← Back
Data updated: Jun 28, 2026

CADILA

Generics
CardiovascularInfectious DiseaseNeurology Execution: Excellent

CADILA is a generic drug manufacturer focused on Cardiovascular, Infectious Disease, Neurology.

2016
Since
11
Drugs
-
Trials
0
New Drugs (2yr)
Modality:

CADILA at a Glance

  • Strong track record with 100% execution quality across 5 trials
  • Fast trial execution (30 months median completion)

CADILA's Key Drugs

CADILA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

CADILA's Recent FDA Approvals

New NDA/BLA approvals for CADILA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

CADILA's Therapeutic Areas

CADILA's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Infectious Disease, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 51%
4 drugs
Infectious Disease 13%
1 drugs
Neurology 13%
1 drugs
Ophthalmology 13%
1 drugs
Oncology 11%
0 drugs Phase 2: 2 Phase 1: 1

CADILA Pipeline Snapshot

CADILA has 3 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 2 Phase 2 and 1 Phase 1.

0
Phase 3
2
Phase 2
1
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Cardiovascular pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 2/2 completed
  • • Speed: 30 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges